Medications

Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Infliximab, Biosimilars, and Anti-TNF. Open the original article for the full details.

This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...

This report describes an investigational drug that appears to reach its intestinal target and produced molecular changes in biopsies from people with fibrostenosing Crohn’s — a form that causes scarring and strictures.

Risk stratification helps identify people with Crohn's who are more likely to develop strictures, fistulas, or need surgery so clinicians can monitor and treat them more aggressively early on. Objective tests like fecal...

Cure8 could only read part of this source from managedhealthcareexecutive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor.

These are phase 3 results showing subcutaneous guselkumab helped more people reach clinical and endoscopic goals than placebo in moderate-to-severe UC and Crohn’s disease; a fully subcutaneous option could offer more...

Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ustekinumab.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from springermedicine.com.

A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...

A new FDA‑approved ustekinumab biosimilar (YESINTEK) is now available in the US for Crohn’s disease and ulcerative colitis, which may increase treatment options and lower costs. Coverage and copay support at launch could...

Cure8 found this source from business-standard.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...

Older adults with IBD have higher cardiovascular risk; medication choice may affect cardiovascular outcomes. This study suggests ustekinumab users had fewer deaths and some cardiac events than vedolizumab users, which...

Cure8 could only read part of this source from devdiscourse.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.

The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.

Cure8 could only read part of this source from money.rediff.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.

Changes in the therapeutics market can affect availability, pricing, and access to Crohn’s treatments. Growth in biosimilars and new drug approvals may influence what options become more widely available.

Cure8 found this source from finance.yahoo.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.

This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the...

A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the...

Patients and clinicians following new, non‑immunosuppressive approaches to UC may be interested because MB310 is an oral live‑biotherapeutic designed to induce remission and is entering clinical testing.

A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.

The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...

This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.

New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...

This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...

If you have IBD or are at risk for colorectal disease, clinicians at the conference highlighted that these conditions are being seen more often and that treatment approaches have shifted toward personalized medicine and...

The article reports rising colorectal disease and IBD rates and describes modern shifts in treatment—topics that can affect screening, treatment options, and specialist care access for people with IBD or colorectal...

Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.

Cure8 indexed this Crohn's and IBD-related source from healio.com. It is tagged for Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis. Open the original article for the full details.

Market reports highlight which companies and drug types are investing in Crohn's disease — that can signal upcoming therapies, trial activity, and availability. Mentions of trials (for example anti‑TL1A) may be of...

Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...

This suggests an existing antibiotic, vancomycin, may help a specific group of IBD patients who also have primary sclerosing cholangitis (PSC), including some who did not respond to other IBD treatments. If confirmed in...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Anti-TNF. The original article is from msn.com.

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Medications. Open the original article for the full details.

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

People with IBD who need advanced therapies may worry about cardiovascular risks linked to some JAK inhibitors. This study suggests, in a real-world cohort with cardiovascular risk factors, short-term (1-year) MACE risk...

Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...

These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Medications. Open the original article for the full details.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Risankizumab, IL-23 inhibitor, and Medications. Open the original article for the full details.

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease and Medications. The original article is from geneonline.com.

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from firstwordpharma.com.